Web-based Genetic Research on Lupus

23andMe

Status: Completed

Conditions: Systemic Lupus Erythematosus

Study type: Observational

Funder types: Industry

Identifiers

NCT02530944

23andMe_SLE001

Details and patient eligibility

About

The goal of this new lupus research study is two-fold: first, to understand the genetic associations found between people's DNA and this disease, and second, to apply this understanding to drug development efforts with the investigator's partners at Pfizer.

Full description

Lupus is a difficult disease to diagnose and one that's difficult to manage, given the lack of specific medicines to treat lupus and the side-effects of current medications. The investigators believe genetics may play a critical role in developing better lupus diagnoses and treatments. If individuals are eligible to participate, the investigators will send a 23andMe DNA saliva kit at no cost. Participants will be asked to take a 15 minute online survey with questions about their lupus experience, symptoms and response to treatments, in addition to five additional bi-monthly short surveys and one final study survey during the 12-month participation. Learn more and join the lupus study today: https://www.23andme.com/lupus/

Enrollment: 5,000 patients

Sex: All

Ages: 6+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosed with lupus by a qualified physician.
• consents to have 23andMe (via a partner) contact the physician to obtain medical record information
• willing to submit a saliva sample for DNA testing and complete online surveys related to condition
• at least 6 years old (minors under 18 require parental consent to enroll)
• access to the internet
• resides in the United States

Exclusion criteria

Trial design

5,000 participants in 1 patient group

Lupus patients

Description:

People diagnosed with Systemic Lupus Erythematosus by a physician